NCT06749795View on ClinicalTrials.gov

LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis (UC)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 24, 2025

Primary Completion Date

January 17, 2026

Study Completion Date

March 24, 2026

Conditions
Ulcerative Colitis (UC)
Interventions
DRUG

LIV001

Orally administered for 8 weeks

DRUG

Placebo

Orally administered for 8 weeks

Trial Locations (1)

Unknown

Centrum Badan Klinicznych Piotr Napora Lekarze Spolka Partnerska, Wroclaw

Sponsors

Lead Sponsor

Liveome Inc.
All Listed Sponsors
lead

Liveome Inc.

INDUSTRY